Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000806724 | SCV000946738 | pathogenic | not provided | 2024-09-03 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Asp162Thrfs*25) in the NTHL1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in NTHL1 are known to be pathogenic (PMID: 25938944, 26559593). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with NTHL1-related conditions. ClinVar contains an entry for this variant (Variation ID: 651377). For these reasons, this variant has been classified as Pathogenic. |
Ambry Genetics | RCV002332650 | SCV002634101 | pathogenic | Hereditary cancer-predisposing syndrome | 2021-03-25 | criteria provided, single submitter | clinical testing | The c.484delG pathogenic mutation, located in coding exon 3 of the NTHL1 gene, results from a deletion of one nucleotide at nucleotide position 484, causing a translational frameshift with a predicted alternate stop codon (p.D162Tfs*25). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Myriad Genetics, |
RCV003458211 | SCV004188368 | pathogenic | Familial adenomatous polyposis 3 | 2023-09-05 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. |